Table 1.

Characteristics of patients with BA-fatigue compared to patients with other ADRs and without ADRs

Patients with BA-fatigue n (%)Patients with other ADRs n (%)Patients without ADRs n (%)
n100 (100%)596 (100%)673 (100%)
Basic demographicsAge (years) (mean ± SD)50.0 ± 14.653.4 ± 13.6 *55.7 ± 14.2 ***
Gender (Female)59 (59%)398 (67%) ns342 (51%) ns
Smoking n (%)25 (25%)97 (16%) *100 (15%) *
BMI (kg/m2) (mean ± SD)25.7 ± 4.425.9 ± 4.7 ns26.6 ± 5.5 ns
BiologicInfliximab22 (22%)53 (9%) ***84 (12%) *
Etanercept13 (13%)177 (30%) ***228 (34%) ***
Rituximab9 (9%)18 (3%) **6 (1%) ***
Tocilizumab8 (8%)29 (5%) ns13 (2%) **
Vedolizumab7 (7%)12 (2%) *7 (1%) ***
IMIDRheumatoid arthritis29 (29%)270 (45%) **272 (40%) *
Crohn’s disease29 (29%)77 (13%) ***88 (13%) ***
Other indication16 (16%)53 (9%) *39 (6%) ***
Combination therapyMethotrexate23 (23%)167 (28%) ns227 (34%) *
ComorbidityPsychiatric disorder11 (11%)49 (8%) ns31 (5%) *
Other comorbidity30 (30%)124 (21%) *102 (15%) ***
Mean burden of ADR ± SD2.9 ± 0.92.4 ± 1.1 ***
  • ns: not significant *p ≤ 0.05 **p ≤ 0.01 ***p ≤ 0.001